Market Place
Sourcing Support
Regenxbio, Novartis & Dyne Near FDA Filing for Muscular Dystrophy
26 May 2026 //
BIOSPACE
Dyne Files BLA for Z-Rostudirsen in Exon 51 Duchenne MD
26 May 2026 //
GLOBENEWSWIRE
Dyne Therapeutics Initiates Phase 3 Forzetto Trial in DMD
20 May 2026 //
GLOBENEWSWIRE
Dyne Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
20 May 2026 //
GLOBENEWSWIRE
Dyne Therapeutics To Participate In Upcoming Investor Conferences
13 May 2026 //
GLOBENEWSWIRE
Dyne Therapeutics Unveils Q1 2026 Financials And Business Updates
11 May 2026 //
GLOBENEWSWIRE
Dyne Announces FORCE CNS Activity in Primates at ASGCT 2026
27 Apr 2026 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Rules
23 Apr 2026 //
GLOBENEWSWIRE
Dyne To Present At AMCP 2026 For Neuromuscular Portfolio
01 Apr 2026 //
GLOBENEWSWIRE
Dyne To Pursue FDA Approval Following Positive Long-Term Data
10 Mar 2026 //
BIOSPACE
Dyne Reports Positive Cardiopulmonary Data in DMD DELIVER Trial
08 Mar 2026 //
GLOBENEWSWIRE
Dyne Starts Phase 3 HARMONIA Trial for Myotonic Dystrophy
08 Mar 2026 //
GLOBENEWSWIRE
Dyne Therapeutics Unveils 2025 Financials And Business Updates
02 Mar 2026 //
GLOBENEWSWIRE
Dyne Therapeutics To Participate In Upcoming Investor Conferences
25 Feb 2026 //
GLOBENEWSWIRE
Dyne Therapeutics To Present Neuromuscular Pipeline At MDA 2026
22 Feb 2026 //
GLOBENEWSWIRE
Dyne Therapeutics` DYNE-101 Gets Orphan Status in Japan for DM1
20 Jan 2026 //
GLOBENEWSWIRE
Dyne Therapeutics To Present At J.P. Morgan Healthcare Conference
07 Jan 2026 //
GLOBENEWSWIRE
Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors
23 Dec 2025 //
GLOBENEWSWIRE
Dyne Closes Upsized Offering; Underwriters Exercise Full Option
11 Dec 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Plans Public Stock Offering
08 Dec 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Z-Rostudirsen Success In (DMD) Trial
08 Dec 2025 //
GLOBENEWSWIRE
Dyne readies FDA push after DMD exon 51 med excels in trial
08 Dec 2025 //
FIERCE BIOTECH
Dyne Therapeutics To Review Duchenne Muscular Dystrophy Trial
07 Dec 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Unveils Q3 2025 Financials & Business Updates
05 Nov 2025 //
GLOBENEWSWIRE
Dyne Reports 1-Year Ph1/2 ACHIEVE Data Of DYNE-101 In DM1
06 Oct 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Appoints Brian Posner To Its Board Of Directors
02 Oct 2025 //
GLOBENEWSWIRE
Dyne Pharma Gets Japan Orphan Status For Dyne-251 In DMD
29 Sep 2025 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Upcoming Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Fda Grants Breakthrough Status to Dyne`s DYNE-251 for Dmd
04 Aug 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Announces Q2 2025 Financial Results and Updates
28 Jul 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Announces Closing of Public Offering of Stock
02 Jul 2025 //
GLOBENEWSWIRE
Dyne Therapeutics secures $275M debt financing from Hercules
30 Jun 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Plans Public Stock Offering
30 Jun 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Prices $200.0M Public Stock Offering
30 Jun 2025 //
GLOBENEWSWIRE
Dyne Therapeutics to Present FSHD Data at FSHD Society Congress
05 Jun 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Q1 2025 Financial Results & Highlights
08 May 2025 //
GLOBENEWSWIRE
Dyne Therapeutics gets EMA Orphan Drug Designation for DYNE-251
24 Apr 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Names Chief Business and Scientific Officers
15 Apr 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Inducement Grants Under Nasdaq LR 5635
14 Apr 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Names Erick J. Lucera CFO
20 Mar 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Inducement Grants Under Nasdaq LR 5635©
20 Mar 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Reveals Long-Term Data from DYNE-251 Trial
16 Mar 2025 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
11 Mar 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Q4 and Full Year 2024 Results
27 Feb 2025 //
GLOBENEWSWIRE
Dyne Therapeutics To Present At 2025 MDA Clinical Conference
14 Feb 2025 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Oppenheimer Healthcare Conference
03 Feb 2025 //
GLOBENEWSWIRE
Dyne Receives FDA Fast Track For DYNE-101 In Myotonic Dystrophy
21 Jan 2025 //
GLOBENEWSWIRE
Dyne Reports DYNE-101 Data, Expansion For DM1 US Approval In 2026
10 Jan 2025 //
GLOBENEWSWIRE
Dyne Therapeutics To Present At 43rd Annual J.P. Morgan Conference
09 Jan 2025 //
GLOBENEWSWIRE
Dyne To Host Webcast On ACHIEVE Trial Data January 10 At 8 AM ET
08 Jan 2025 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Upcoming Investor Conferences
07 Nov 2024 //
GLOBENEWSWIRE
Dyne Presents FORCE Platform Data At World Muscle Society
09 Oct 2024 //
GLOBENEWSWIRE
Dyne To Present At Chardan Genetic Medicines Conference
23 Sep 2024 //
GLOBENEWSWIRE
Three execs resign as Dyne posts mixed data for DMD candidate
04 Sep 2024 //
FIERCE BIOTECH
Dyne Therapeutics Announces Key Leadership Appointments
03 Sep 2024 //
GLOBENEWSWIRE
Dyne Therapeutics to Present at Morgan Stanley Global Healthcare Conference
29 Aug 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Reports Q2 2024 Results And Recent Business Highlights
12 Aug 2024 //
GLOBENEWSWIRE
Dyne Therapeutics Presents FORCE™ Platform Data for Pompe Disease Therapy
24 Jun 2024 //
GLOBENEWSWIRE
Dyne Presents Preclinical FSHD Data At FSHD Society Congress
13 Jun 2024 //
GLOBENEWSWIRE
